UPDATE: Piper Jaffray Raises Price Target on Trius Therapeutics to $15


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


According to Piper Jaffray, Trius Therapeutics (NASDAQ: TSRX) price target is raised to $15.Piper Jaffray said that following positive results from the 1st pivotal tedizolid trial, Trius is a Top Pick for 2012. “We reiterate our Overweight rating and are increasing our price target to $15 from $12.”Trius Therapeutics closed on Friday at $7.15.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: Analyst ColorPrice TargetAnalyst RatingsPiper Jaffray